Agencia Española de Medicamentos y Productos Sanitarios. PROSPECTO SLINDA 4 MG COMPRIMIDOS RECUBIERTOS CON PELICULA. (n.d.). Aemps.Es. Retrieved January 9, 2023, from https://cima.aemps.es/cima/dochtml/p/84603/P_84603.html
Book of Abstracts: The 15th Congress of the European Society of Contraception and Reproductive Health. The European Journal of Contraception & Reproductive Health Care. 2018;23(sup1):1-143.
Centeno, Indira M., et al. “Efecto de un anticonceptivo oral con drospirenona/etinilestradiol (3 mg – 30 mg) sobre el hiperandrogenismo clínico y bioquímico en pacientes con síndrome de ovario poliquístico.” Fac.Rev. Medicina. (Caracas) , 2011, págs. 60–63, https://pesquisa.bvsalud.org/portal/resource/pt/lil-637406.
Chiara Del Savio M, De Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020 Jul;13(7):685-694.
Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019 Dec;98(12):1549-1557.
Sales Vieira C, Celis C, Galán G, Hernández L, et al. Drospirenone: a Latin American perspective for oestrogen-free oral contraception. Eur J Contracept Reprod Health Care. 2021 Feb;26(1):73-78.